New York, USA:
Symbio, a specialized therapeutic clinical research organization (CRO), is expanding it’s global presence with the opening of a new office and legal entity in Melbourne, Australia.
While Symbio has previously managed trials within Australia, the establishment of a dedicated local presence underscores the country’s growing strategic importance in global clinical research. The move reflects Symbio’s commitment to expanding its capabilities in the region and enhancing support for clients conducting trials in Australia. Access to exceptional investigators specializing in dermatology, combined with a strong regulatory environment and attractive government incentives for qualifying activities make Australia a key part of global development plans.
The new Melbourne office positions Symbio to further strengthen partnerships, streamline operations, and continue to contribute to the advancement of innovative therapies worldwide.
About Symbio:
With main offices in California, New York, Germany, France, and Australia, Symbio is a specialized global therapeutic clinical research organization with proven expertise in dermatology, aesthetics, inflammation, and gastroenterology across Phases I-IV, medical device, and non-interventional studies. Symbio offers full service CRO capabilities for both drug and device development. These services are further supported by a dedicated laboratory, manufacturing and packaging facility focused on topical formulation, research and development as well as small scale manufacturing, and clinical packaging and labelling services for all dosage forms.
